Corporate / M&A

Capital Markets

Financing and Investment Products

IP / IT

Data Protection

Employment and Executive Compensation

Competition

Regulatory

Vectivio

Homburger News

Share-Image Teamplate Deals-and-Cases

On May 22, 2023, VectivBio Holding AG (Nasdaq: VECT), Basel (Switzerland), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an all-cash public tender offer to acquire all outstanding shares in VectivBio for USD 17 per share, with an estimated aggregate consideration of approximately USD 1 bn, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The offer is subject to customary conditions and expected to close in mid-2023. VectivBio&#8217;s board of directors unanimously recommends the offer. Orbimed, Forbion and Versant Ventures, and VectivBio&#8217;s directors and officers jointly representing 28.6% of VectivBio&#8217;s shareholdings, entered into tender and support agreements in connection with, and in support of, the offer.
Homburger AG serves as legal and tax advisor to VectivBio on the transaction. The Homburger team includes Andreas Müller, Margrit Marti, Oliver Kneubühl, Francesco Bernasconi, Oliver Dalla Palma, Daniel Wenzinger and Carolina Rodriguez (all Corporate / M&amp;A), Lorenzo Togni (Capital Markets), Stefan Oesterhelt, Philippe Gobet and Kevin Müller (all Tax), Stefan Bindschedler (Financing and Investment Products), Luca Dal Molin (IP / IT; Data Protection), Angela Casey (Employment and Executive Compensation), and Richard Stäuber and Christoph Grüninger (Competition, Regulatory).

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Healthcare / Life Sciences

On December 13, 2022, Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that it has entered into a definitive agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump, an insulin delivery solution.
The consideration includes a previous strategic investment of CHF 8.0 m, an upfront cash payment of CHF 62.4 m, and additional contingent earnout payments of up to CHF 129.6 m, in aggregate, payable upon the achievement of certain milestones. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in January 2023.
Homburger, who also advised AMF Medical on its previous financing rounds, acts as transaction counsel to AMF Medical SA and its shareholders. The Homburger team comprises Andreas Müller, Margrit Marti and Léonard Aeschlimann Perales (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin and Joel Fink (both IP / IT; Healthcare / Life Sciences), Stefan Oesterhelt, Kevin Müller and Philippe Weber (all Tax), Richard Stäuber and Allegra Arnold (both Competition; Healthcare / Life Sciences), and Marc Bircher and Sebastian Wyler (both Employment and Executive Compensation).

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

On October 13, 2022, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the release of its interim data from the first five of nine patients in its ongoing Phase 2 STARS Nutrition clinical trial, the pricing of a USD 125 m underwritten offering of ordinary shares, and an amendment to its financing agreement with Kreos Capital VI (UK) Limited, including the right to receive additional warrants under certain conditions.
The underwritten offering consists of 16,700,000 ordinary shares at an offering price of USD 7.50 per share. Investors include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion&#8217;s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors.
The Homburger team includes partner Andreas Müller, associates Margrit Marti and Oliver Kneubühl, and junior associate Julien Di Sabato (all Capital Markets; Corporate / M&amp;A), partner Jürg Frick, associates Simone Gloor and Stefan Bindschedler, and junior associate Thibault Sieber (all Financing and Investment Products), partner Stefan Oesterhelt and associate Kevin Müller (both Tax), and partner Luca Dal Molin (IP / IT).

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Kevin
Müller

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Berücksichtigung der Berufskosten bei COVID-19-bedingtem Homeoffice: Kantonale Praxen im Überblick

Join the Team

Kevin Müller

Career

Languages

Teams

KevinMüller

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Berücksichtigung der Berufskosten bei COVID-19-bedingtem Homeoffice: Kantonale Praxen im Überblick

Join the Team

Kevin Müller

Career

Languages

Teams

Kevin
Müller